The Valiant™ Captivia™ system is designed to treat all lesions of the descending thoracic aorta.
The Valiant™ thoracic stent graft with the Captivia™ delivery system is indicated for the endovascular repair of all lesions of the descending thoracic aorta (DTA) in patients having appropriate anatomy, including:
The Valiant™ thoracic stent graft with the Captivia™ delivery system is contraindicated in:
The long-term safety and effectiveness of the Valiant™ thoracic stent graft with the Captivia™ delivery system has not been established. All patients should be advised that endovascular treatment requires lifelong, regular follow-up to assess the integrity and performance of the implanted endovascular stent graft. Patients with specific clinical findings (for example, enlarging aneurysm (> 5 mm), endoleaks, migration, inadequate seal zone, or continued flow into the false lumen in the case of a dissection) should receive enhanced follow-up. Specific follow-up guidelines are described in the instructions for use. The Valiant™ thoracic stent graft with the Captivia™ delivery system is not recommended in patients who cannot undergo, or who will not be compliant with, the necessary preoperative and post-operative imaging and implantation procedures as described in the instructions for use. Strict adherence to the Valiant™ thoracic stent graft sizing guidelines as described in the instructions for use is expected when selecting the device size. Sizing outside of this range can potentially result in endoleak, fracture, migration, infolding, or graft wear. As cautioned in the instructions for use, a balloon should never be used when treating a dissection. The safety and effectiveness of the Valiant™ thoracic stent graft with the Captivia™ delivery system has not been evaluated in some patient populations. Refer to the product instructions for use for details.
Non-clinical testing has demonstrated that the Valiant™ thoracic stent graft is MR Conditional. It can be scanned safely in both 1.5T and 3.0T MR systems under specific conditions as described in the product instructions for use. For additional information regarding MRI, refer to the product instructions for use.
Potential adverse events include, but are not limited to, access failure, access site complications (e.g., spasm, trauma, bleeding, rupture, dissection), adynamic ileus, allergic reaction (to contrast, antiplatelet therapy, stent graft material), amputation, anaesthetic complications, aortic expansion (e.g., aneurysm, false lumen), aneurysm rupture, angina, arrhythmia, arterial stenosis, atelectasis, blindness, bowel ischemia/infarction, bowel necrosis, bowel obstruction, branch vessel occlusion, buttock claudication, cardiac tamponade, catheter breakage, cerebrovascular accident (CVA)/stroke, change in mental status, coagulopathy, congestive heart failure, contrast toxicity, conversion to surgical repair, death, deployment difficulties/failures, dissection/perforation/rupture of the aortic vessel and/or surrounding vasculature, embolism, endoleak(s), excessive or inappropriate radiation exposure, extrusion/erosion, failure to deliver stent graft, femoral neuropathy, fistula (including aortobronchial, aortoenteric, aortoesophageal, arteriovenous, and lymph), gastrointestinal bleeding/complications, genitourinary complications, hematoma, hemorrhage/bleeding, hypotension/hypertension, infection or fever, insertion or removal difficulties, intercostal pain, intramural hematoma, leg/foot edema, lymphocele, myocardial infarction, neuropathy, occlusion — venous or arterial, pain/reaction at catheter insertion site, paralysis, paraparesis, paraplegia, paresthesia, perfusion of the false lumen, peripheral ischemia, peripheral nerve injury, pneumonia, post-implant syndrome, procedural/post-procedural bleeding, prosthesis dilatation/infection/rupture/thrombosis, pseudoaneurysm, pulmonary edema, pulmonary embolism, reaction to anaesthesia, renal failure, renal insufficiency, reoperation, respiratory depression/failure, sepsis, seroma, shock, spinal neurological deficit, stent graft material failure (including breakage of metal portion of device)/migration/misplacement/occlusion/twisting/kinking, transient ischemic attack (TIA), thrombosis, tissue necrosis, vascular ischemia, vascular trauma, wound dehiscence, wound healing complications, wound infection.
Reference product instructions for use for more information regarding indications, warnings, precautions, contraindications, and adverse events.
Caution: Federal law (United States) restricts this device to sale by or on the order of a physician.
UC202411206 EN
Find more information, including other available configurations, for Valiant™ thoracic stent graft with Captivia™ delivery system.
Your information will be used and protected in accordance with our {link}
Hours: 8:00 a.m. - 8:00 p.m. EST
Phone: 763-514-4000
Toll-free: 800-633-8766
Just to confirm, is this the product or product type that interests you?
{{productNamePlaceholder}}
OR
Before we get started, what best describes you?
If you subscribe to email updates, you can unsubscribe anytime via the link in each email. We use technology to measure email opens and clicks, to improve our communications and provide relevant content. For details, see our {link}
Your personal data will be used to manage your relationship with Medtronic in accordance with our {link}
If you consent to receive emails, you can unsubscribe anytime via the link in each email. We use technology that measures email opens and clicks, to improve our communications and provide relevant content. For details, see our {link}
